The Journal of Practical Medicine ›› 2023, Vol. 39 ›› Issue (5): 613-618.doi: 10.3969/j.issn.1006⁃5725.2023.05.015

• Clinical Research • Previous Articles     Next Articles

The efficacy of mindfulness ⁃ based cognitive therapy combined with duloxetine for patients with somato⁃ form disorder

LI Yuanyuan,WANG Ce,DING Xiaochao,YU Xuezhu,LIU Jie,LIU Zhuowei.   

  1. Hebei Provincial Mental Health Center,Hebei Key Laboratory of Major Mental and Behavioral Disorders,the Sixth Clinical Medical College of Hebei University,Baoding 071000,China

  • Online:2023-03-10 Published:2023-03-10

Abstract:

Objective To evaluate the efficacy of combination therapy of mindfulness⁃based cognitive thera⁃ py(MBCT)and duloxetinein patients with somatoform disorder. Methods This was an 8⁃weeks randomized control study. Totally 80 patients with somatoform disorder who met the criteria for inclusion were recruited. All patients were randomly assigned to one of two groups:MBCT and Duloxetine treatment(n = 38)or Duloxetine control(n = 42). The Five Facet Mindfulness Questionaire(FFMQ)and Hamilton Anxiety Scale(HAMA)were administered to evalu⁃ ate the improvement effect of mindfulness skills and anxiety symptoms. Results ANOVA for repeated measurement results showed that the mindfulness skills of the combined treatment group were significantly improved,and the dif⁃ ferences were statistically significant(F = 96.462,P < 0.001). In the combined treatment group,the mindfulness skills of the higher education group were improved more than those of the lower education group,and the differences were statistically significant(F = 34.485,P < 0.001). The scores of each dimension of FFMQ in the combined treat⁃ ment group were significantly improved with the extension of time,and the differences were statistically significant. In terms of efficacy,anxiety was relieved earlier in the combined treatment group. Conclusion MBCT combined with duloxetine can significantly improve mindfulness skills and anxiety symptoms.

Key words:

mindfulness?based cognitive, duloxetine, somatoform disorder, efficacy